Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | ILK | Q13418 | 1/20 | 0.44 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941679 | 0.86 | PARP1 (0.46) | PARP1ADORA1KITCSF1RLOXL2 | |
| SCHEMBL10204398 | 0.84 | ALDH1A1 (0.45) | PARP1SMYD3 | |
| SCHEMBL1166333 | 0.84 | ALDH1A1 (0.39) | PARP1LOXL2SMYD3 | |
| SCHEMBL4937449 | 0.83 | LOXL2 (0.46) | KITLOXL2 | |
| SCHEMBL4941722 | 0.83 | SMYD3 (0.60) | PARP1ADORA1KDRKITSMYD3 | |
| SCHEMBL4310539 | 0.83 | CYP4F2 (0.46) | CSF1RLOXL2SMYD3IGF1R | |
| SCHEMBL13945542 | 0.82 | PARP1 (0.48) | PARP1ADORA1KDRPDGFRBKIT | |
| SCHEMBL4944793 | 0.81 | ALDH1A1 (0.38) | RAF1 | |
| SCHEMBL12256511 | 0.80 | CSF1R (0.47) | PARP1ADORA1KDRPDGFRBKIT | |
| SCHEMBL28728220 | 0.80 | GABRA1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1891047-A4 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1891047-A2 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer HealthCare AG (DE) | 2008-02-27 | — | — | EP | disclosed |
| CN-101133054-A | 1, 3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents | BAYER PHARMACEUTICALS CORP (US) | 2008-02-27 | — | — | CN | disclosed |
| EP-1858893-A1 | 1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006133006-A2 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006096338-A1 | 1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006023707-A2 | 2-AMINOTHIOPHENECARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | PARP1 834/4885ADORA1 101/4885KDR 2408/4885 |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | MCL1, HDAC5, HDAC6 | PARP1 184/4885ADORA1 2875/4885KDR 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.